Europe PMC
Nothing Special   »   [go: up one dir, main page]

Europe PMC requires Javascript to function effectively.

Either your web browser doesn't support Javascript or it is currently turned off. In the latter case, please turn on Javascript support in your web browser and reload this page.

This website requires cookies, and the limited processing of your personal data in order to function. By using the site you are agreeing to this as outlined in our privacy notice and cookie policy.

A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis.

Show less

Author information

Affiliations

  • 1. Department of Molecular Medicine, University of Pavia, Pavia, Italy.
      Authors
    • Bellofiore C 1, 2, 5
    • Nanci M 1, 2
    • Nuvolone M 1, 2
    • Arcaini L 1, 4
    • Merlini G 1, 2
    • Palladini G 1, 2
    • Milani P 1, 2
    (7 authors)
  • 2. Amyloidosis Research and Treatment Centre, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) Policlinico San Matteo, Pavia, Italy.
      Authors
    • Bellofiore C 1, 2, 5
    • Benvenuti P 2
    • Basset M 2
    • Foli A 2
    • Nanci M 1, 2
    • Nuvolone M 1, 2
    • Guida G 2
    • Attanasio A 2
    • Mussinelli R 2
    • Merlini G 1, 2
    • Palladini G 1, 2
    • Milani P 1, 2
    (12 authors)
  • 3. Division of Haematology, University of Torino, Torino, Italy.
      Authors
    • Mina R 3
    • Cani L 3
    • Oliva S 3
    • Bringhen S 3
    (4 authors)
  • 4. Division of Haematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
      Authors
    • Mangiacavalli S 4
    • Cartia CS 4
    • Masoni V 4
    • Palumbo M 4
    • Arcaini L 1, 4
    (5 authors)
  • 5. Hematology Unit, ARNAS Garibaldi, Catania, Italy.
      Authors
    • Bellofiore C 1, 2, 5
    • Consoli U 5
    (2 authors)
    • Show all (6)

ORCIDs linked to this article

Hematological Oncology, 01 Jul 2024, 42(4):e3289
https://doi.org/10.1002/hon.3289 PMID: 38824453 

Abstract 

Daratumumab-based regimens are the new standard of care for newly diagnosed patients with AL amyloidosis based on the results of the ANDROMEDA study. However, real-world data on daratumumab efficacy in upfront therapy in unselected patients are scanty. In the framework of a prospective observational study, we investigated the efficacy and safety of daratumumab in 88 newly diagnosed patients, including subjects with IIIb cardiac stage (26%) or myeloma defining events (29%). Daratumumab was administered with bortezomib in 50 (56%) patients, lenalidomide in 31 (35%), and monotherapy in 7 (8%). The rate of serious adverse events was low (16%). The overall hematologic response rate was 75% with 52 (59%) patients attaining at least a very good partial response (VGPR) at six months. Amongst patients evaluable for organ response, the rate of cardiac and renal responses at 6 months was 31% and 21%, respectively. Comparing stage IIIb patients with the remaining ones, the rate of profound hematologic response was not significantly different (≥VGPR 57% vs. 59%, p 0.955) likewise the rate of cardiac (33% vs. 30%, p 0.340) and renal (40% vs. 16%, p 0.908) responses. Daratumumab-based regimens demonstrated to be safe and effective in treatment-naïve AL amyloidosis even in advanced stage disease.

Full text links 

Read article at publisher's site: https://doi.org/10.1002/hon.3289

Citations & impact 

This article has not been cited yet.

Impact metrics

Alternative metrics

Altmetric item for https://www.altmetric.com/details/164102621
Altmetric
Discover the attention surrounding your research
https://www.altmetric.com/details/164102621

Similar Articles 

To arrive at the top five similar articles we use a word-weighted algorithm to compare words from the Title and Abstract of each citation.